Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 13, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction involving Mr. R Bondy, who acquired a beneficial interest in 2 Ordinary Shares. These shares were purchased under a Personal Equity Plan on October 11, 2005, at a price of GBP 14.4464 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the aforementioned share transaction.
Investor Verification Points
- Verify the identity of Mr. R Bondy and his role within GlaxoSmithKline plc.
- Confirm the transaction date of October 11, 2005, and the purchase price of GBP 14.4464 per share.
- Note that the transaction involved only 2 Ordinary Shares acquired via a Personal Equity Plan.
- Understand that this filing does not reflect broader company financial performance or strategic changes.